Study demonstrates high bioavailability of AvailOm omega-3 lysine complex

A recent study demonstrated the bioavailability of Evonik’s AvailOm omega-3 lysine complex. The novel technology combines omega-3 fatty acids with the amino acid L-lysine to enhance the absorption of omega-3s in the body.

A recent study demonstrated the bioavailability of Evonik’s (Essen, Germany) AvailOm omega-3 lysine complex. The novel technology combines omega-3 fatty acids with the amino acid L-lycine to enhance the absorption of omega-3s in the body. The study, published in Prostaglandins, Leukotrienes and Essential Fatty Acids1 found that compared to oil-based ethyl ester formulation, the omega-3 lysine complex has five times the bioavailability.

“The results of this first in-human study provide compelling evidence that can improve the efficacy of omega-3 supplementation. Not only does the administration of EPA and DHA in the form of its lysine salt provide a novel and effective way to increase plasma levels of these important fatty acids, the stability and technical properties of the omega-3 lysine complex provide additional advantages that will allow the development of novel product formulations that may require lower doses,” said Renger Witkamp, professor of Nutritional Biology at Wageningen University & Research, in a press release. “This study represents exciting opportunities for the optimization of omega-3 supplementation using the lysine complex.”

“Evonik’s omega-3 lysine complex solves many challenges in the development of highly concentrated and yet convenient food supplements, addressing the needs of various consumer groups, such as pregnant women, mothers, and healthy agers,” said Christopher Studte, director new health ingredients at Evonik Health Care, in a press release.

AvailOm is available in three grades: AvailOm50 High DHA Algae, AvailOm50 High DHA, AvailOm50 High EPA. The ingredient is in powder form, with a combined 50% eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as free fatty acid by weight.

Reference

  1. Manusama K et al. “In vitro dissolution behaviour and absorption in humans of a novel mixed l-lysine salt formulation of EPA and DHA.” Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 164 (2021)